Photo from wikipedia
Little is known about the comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants (NOAC) compared to warfarin in Chinese atrial fibrillation (AF) patients. Our aim was to compare… Click to show full abstract
Little is known about the comparative effectiveness and safety of non–vitamin K antagonist oral anticoagulants (NOAC) compared to warfarin in Chinese atrial fibrillation (AF) patients. Our aim was to compare the ischemic stroke risk reduction and incidence of intracranial hemorrhage (ICH) of warfarin in relation to quality of anticoagulation control (as reflected by time in therapeutic range [TTR]), and to dabigatran and rivaroxaban in a real‐world cohort of Chinese AF patients.
Keywords:
atrial fibrillation;
fibrillation;
warfarin;
safety;
chinese patients;
dabigatran rivaroxaban
Journal Title: Clinical Cardiology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cardiology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!